BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

429 related articles for article (PubMed ID: 22046961)

  • 21. Comparison of patient-reported outcomes during treatment with adjustable- and fixed-dose budesonide/formoterol pressurized metered-dose inhaler versus fixed-dose fluticasone propionate/salmeterol dry powder inhaler in patients with asthma.
    O'Connor RD; Patrick DL; Parasuraman B; Martin P; Goldman M
    J Asthma; 2010 Mar; 47(2):217-23. PubMed ID: 20170333
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease.
    Welte T; Miravitlles M; Hernandez P; Eriksson G; Peterson S; Polanowski T; Kessler R
    Am J Respir Crit Care Med; 2009 Oct; 180(8):741-50. PubMed ID: 19644045
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparable long-term safety and efficacy of a novel budesonide/formoterol pressurized metered-dose inhaler versus budesonide/formoterol Turbuhaler in adolescents and adults with asthma.
    Morice AH; Hochmuth L; Ekelund J; Thorén A; Puterman AS
    Pulm Pharmacol Ther; 2008; 21(1):32-9. PubMed ID: 17118686
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Short-term effects of inhalative tiotropium/formoterol/budenoside versus tiotropium/formoterol in patients with newly diagnosed chronic obstructive pulmonary disease requiring surgery for lung cancer: a prospective randomized trial.
    Bölükbas S; Eberlein M; Eckhoff J; Schirren J
    Eur J Cardiothorac Surg; 2011 Jun; 39(6):995-1000. PubMed ID: 20970351
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and Safety of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler in Chinese Patients with COPD: A Subgroup Analysis of KRONOS.
    Wang C; Yang T; Kang J; Chen R; Zhao L; He H; Assam PN; Su R; Bourne E; Ballal S; DeAngelis K; Dorinsky P
    Adv Ther; 2020 Apr; 37(4):1591-1607. PubMed ID: 32152869
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD.
    Donohue JF; Maleki-Yazdi MR; Kilbride S; Mehta R; Kalberg C; Church A
    Respir Med; 2013 Oct; 107(10):1538-46. PubMed ID: 23830094
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Budesonide/formoterol in a single inhaler versus inhaled corticosteroids alone in the treatment of asthma.
    Tal A; Simon G; Vermeulen JH; Petru V; Cobos N; Everard ML; de Boeck K
    Pediatr Pulmonol; 2002 Nov; 34(5):342-50. PubMed ID: 12357478
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and safety of high-dose budesonide/formoterol (Symbicort) compared with budesonide administered either concomitantly with formoterol or alone in patients with persistent symptomatic asthma.
    Jenkins C; Kolarikova R; Kuna P; Caillaud D; Sanchis J; Popp W; Pettersson E
    Respirology; 2006 May; 11(3):276-86. PubMed ID: 16635085
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Bronchodilator responsiveness and onset of effect with budesonide/formoterol pMDI in COPD.
    Celli BR; Tashkin DP; Rennard SI; McElhattan J; Martin UJ
    Respir Med; 2011 Aug; 105(8):1176-88. PubMed ID: 21531124
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of the efficacy and safety of arformoterol 15 microg twice daily and arformoterol 30 microg once daily in COPD: a single-dose, multicenter, randomized, modified-blind, two-way crossover study.
    Panettieri RA; MacIntyre N; Sims M; Kerwin E; Fogarty C; Noonan M; Claus R; Andrews WT
    Clin Ther; 2009 Aug; 31(8):1716-23. PubMed ID: 19808130
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and tolerability of high-dose budesonide/formoterol via Turbuhaler® in Japanese patients with asthma: a randomized, double-blind, crossover, active comparator-controlled, phase III study.
    Saito T; Hasunuma T
    Clin Drug Investig; 2012 Jan; 32(1):51-61. PubMed ID: 22024920
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies.
    Kerwin EM; Gotfried MH; Lawrence D; Lassen C; Kramer B
    Clin Ther; 2011 Dec; 33(12):1974-84. PubMed ID: 22177371
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Once-daily dosing with budesonide/formoterol compared with twice-daily budesonide/formoterol and once-daily budesonide in adults with mild to moderate asthma.
    Kuna P; Creemers JP; Vondra V; Black PN; Lindqvist A; Nihlen U; Vogelmeier C
    Respir Med; 2006 Dec; 100(12):2151-9. PubMed ID: 16701989
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Triple therapy with budesonide/glycopyrrolate/formoterol fumarate with co-suspension delivery technology versus dual therapies in chronic obstructive pulmonary disease (KRONOS): a double-blind, parallel-group, multicentre, phase 3 randomised controlled trial.
    Ferguson GT; Rabe KF; Martinez FJ; Fabbri LM; Wang C; Ichinose M; Bourne E; Ballal S; Darken P; DeAngelis K; Aurivillius M; Dorinsky P; Reisner C
    Lancet Respir Med; 2018 Oct; 6(10):747-758. PubMed ID: 30232048
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.
    Boscia JA; Pudi KK; Zvarich MT; Sanford L; Siederer SK; Crim C
    Clin Ther; 2012 Aug; 34(8):1655-66.e5. PubMed ID: 22789766
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Budesonide/formoterol maintenance and reliever therapy via Turbuhaler versus fixed-dose budesonide/formoterol plus terbutaline in patients with asthma: phase III study results.
    Atienza T; Aquino T; Fernández M; Boonsawat W; Kawai M; Kudo T; Ekelund J; Ivanov S; Carlsson LG
    Respirology; 2013 Feb; 18(2):354-63. PubMed ID: 23126237
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Comparison of adjustable- and fixed-dose budesonide/formoterol pressurized metered-dose inhaler and fixed-dose fluticasone propionate/salmeterol dry powder inhaler in asthma patients.
    Busse WW; Shah SR; Somerville L; Parasuraman B; Martin P; Goldman M
    J Allergy Clin Immunol; 2008 Jun; 121(6):1407-14, 1414.e1-6. PubMed ID: 18455221
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Fast onset of effect of budesonide/formoterol versus salmeterol/fluticasone and salbutamol in patients with chronic obstructive pulmonary disease and reversible airway obstruction.
    Lindberg A; Szalai Z; Pullerits T; Radeczky E
    Respirology; 2007 Sep; 12(5):732-9. PubMed ID: 17875063
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Patient-reported outcomes in adults with moderate to severe asthma after use of budesonide and formoterol administered via 1 pressurized metered-dose inhaler.
    Chervinsky P; Baker J; Bensch G; Parasuraman B; Boggs R; Martin P; O'Dowd L
    Ann Allergy Asthma Immunol; 2008 Nov; 101(5):463-73. PubMed ID: 19055199
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of persistent asthma with Symbicort (budesonide/formoterol inhalation aerosol): an inhaled corticosteroid and long-acting beta2-adrenergic agonist in one pressurized metered-dose inhaler.
    Berger WE; Noonan MJ
    J Asthma; 2010 May; 47(4):447-59. PubMed ID: 20528601
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.